BRIEF-Histogenics on track for top-line one year superiority data, potential BLA filing in Q3 of 2018
June 27, 2017 at 16:14 PM EDT
* Histogenics completes enrollment for phase 3 clinical trial of neocart® to treat knee cartilage damage
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.